Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Clinical Pharmacokinetics of Intranasal Sumatriptan

Fuseau, Eliane, Petricoul, Olivier, Moore, Katy HP, Barrow, Andrew, Ibbotson, Tim · 2002 · Clinical Pharmacokinetics

Abstract

A substantial proportion of migraine patients have gastric stasis and suffer severe nausea and/or vomiting during their migraine attack. This may lead to erratic absorption from the gastrointestinal tract and make oral treatment unsatisfactory. For such patients, an intranasal formulation may be advantageous. Sumatriptan is a potent serotonin 5HT(1B/1D) agonist widely used in the treatment of migraine; the effectiveness of the intranasal formulation (20mg) has been well established in several clinical studies. This article reviews the pharmacokinetics of intranasal sumatriptan and includes comparisons with oral and subcutaneous administration. After intranasal administration, sumatriptan is directly and rapidly absorbed, with 60% of the maximum plasma concentration (C(max)) occurring at 30 minutes after administration of a single 20mg dose. Following intranasal administration, approximately 10% more sumatriptan is absorbed probably via the nasal mucosa when compared with oral administration. Mean C(max) after a 20mg intranasal dose is approximately 13.1 to 14.4 ng/mL, with median time to C(max) approximately 1 to 1.75 hours. When given as a single dose, intranasal sumatriptan displays dose proportionality in its extent of absorption and C(max) over the dose range 5 to 10mg, but not between 5 and 20mg for C(max). The elimination phase half-life is approximately 2 hours, consistent with administration by other routes. Sumatriptan is metabolised by monoamine oxidase (MAO; predominantly the A isozyme, MAO-A) to an inactive metabolite. Coadministration with a MAO-A inhibitor, moclobemide, leads to a significant increase in sumatriptan plasma concentrations and is contraindicated. Single-dose pharmacokinetics in paediatric and adolescent patients following intranasal sumatriptan were studied to determine the effect of changes in nasal morphology during growth, and of body size, on pharmacokinetic parameters. The pharmacokinetic profile observed in adults was maintained in the adolescent population; generally, factors such as age, bodyweight or height did not significantly affect the pharmacokinetics. In children below 12 years, C(max) is comparable to that seen in adolescents and adults, but total exposure (area under the concentration-time curve from zero to infinity) was lower in children compared with older patients, especially in younger children treated with 5mg. Clinical experience suggests that intranasal sumatriptan has some advantages over the tablet (more rapid onset of effect and use in patients with gastrointestinal complaints) or subcutaneous (noninvasive and fewer adverse events) formulations.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003088-200241110-00002

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 0 references

Research works printed but not linked: 8

  1. Dixon, 1993, Drug Metab Dispos, 21, 761
  2. Su, 1996, Drug Metab Dispos, 24, 884
  3. Christensen, 2000, Clin Pharmacol Ther, 67, 103
  4. Barrow, 1997, Biopharm Drug Dispos, 18, 443, 10.1002/(SICI)1099-081X(199707)18:5<443::AID-BDD35>3.0.CO;2-D · doi:10.1002/(sici)1099-081x(199707)18:5<443::aid-bdd35>3.0.co;2-d
  5. Wang, 1998, Biopharm Drug Dispos, 19, 571, 10.1002/(SICI)1099-081X(199812)19:9<571::AID-BDD142>3.0.CO;2-O · doi:10.1002/(sici)1099-081x(199812)19:9<571::aid-bdd142>3.0.co;2-o
  6. Moore, 2001, Cephalalgia, 21, 533
  7. Williams, 1997, Cephalalgia, 17, 417
  8. Williams, 1997, Cephalalgia, 17, 408

Cited by

See all 69

Metadata

Authors
Fuseau, E., Petricoul, O., Moore, K. H., Barrow, A., & Ibbotson, T.
Affiliations
  • Sciences Po Aix (FR)
  • GlaxoSmithKline (United Kingdom) (GB)
Corresponding author
Moore, Katy HP
Venue
Clinical Pharmacokinetics
Published
2002
Volume
41
Issue
11
Pages
801-811
ISSN
0312-5963 (ISSN-L)
OpenAlex
W1983027274
Cited by
69
References
0
Citations by year
2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 4 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 6
FWCI
0.27
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
sumatriptan, intranasal administration, pharmacokinetics, migraine, nasal absorption, dose proportionality, elimination half-life, monoamine oxidase A, moclobemide, drug-drug interactions, pediatric pharmacokinetics, adolescents, gastric stasis, bioavailability, subcutaneous administration
MeSH terms
Administration, Intranasal, Adolescent, Adult, Animals, Child, Clinical Trials as Topic, Dose-Response Relationship, Drug, Drug Interactions, Humans, Kidney Diseases, Liver Diseases, Migraine Disorders, Serotonin Receptor Agonists, Sumatriptan

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Pharmacokinetics of Intranasal Sumatriptan. https://app.cochat.ai/papers/10.2165/00003088-200241110-00002
The paper
Fuseau, E., Petricoul, O., Moore, K. H., Barrow, A., & Ibbotson, T. (2002). Clinical Pharmacokinetics of Intranasal Sumatriptan. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200241110-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.